Literature DB >> 20827662

Stanniocalcin 1 induction by thyroid hormone depends on thyroid hormone receptor β and phosphatidylinositol 3-kinase activation.

L C Moeller1, N E Haselhorst, A M Dumitrescu, X Cao, H Seo, S Refetoff, K Mann, O E Janssen.   

Abstract

CONTEXT: Thyroid hormone (TH) mediated changes in gene expression were thought to be primarily initiated by the nuclear TH receptor (TR) binding to a thyroid hormone response element in the promoter of target genes. A recently described extranuclear mechanism of TH action consists of the association of TH-liganded TRβ with phosphatidylinositol 3-kinase (PI3K) in the cytosol and subsequent activation of the PI3K pathway.
OBJECTIVE: The aim of this study was to examine the effect of TH, TRβ and PI3K on stanniocalcin 1 (STC1) expression in human cells.
DESIGN: We treated human skin fibroblasts with triiodothyronine (T3) in the absence or presence of the PI3K inhibitor LY294002, a dominant negative PI3K subunit, Δp85α, and the protein synthesis inhibitor cycloheximide (CHX). The role of the TRβ was studied in cells from patients with resistance to thyroid hormone (RTH). STC-1 mRNA expression was measured by real-time PCR.
RESULTS: We found an induction of STC1 by T3 in normal cells, but less in cells from subjects with RTH (2.7 ± 0.2 vs. 1.6 ± 0.04, P < 0.01). The effect of T3 was completely abrogated by blocking PI3K with LY294002 (3.9 ± 0.5 vs. 0.85 ± 0.5; P < 0.05) and greatly reduced after transfection of a dominant negative PI3K subunit, demonstrating dependency on the PI3K pathway.
CONCLUSION: These results establish STC1 as a TH target gene in humans. Furthermore, we show that STC1 induction by TH depends on both TRβ and PI3K activation. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20827662      PMCID: PMC5800749          DOI: 10.1055/s-0030-1262860

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  25 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Physiological and molecular basis of thyroid hormone action.

Authors:  P M Yen
Journal:  Physiol Rev       Date:  2001-07       Impact factor: 37.312

3.  Stanniocalcin-1 is a naturally occurring L-channel inhibitor in cardiomyocytes: relevance to human heart failure.

Authors:  David Sheikh-Hamad; Roger Bick; Gang-Yi Wu; Birgitte Mønster Christensen; Peter Razeghi; Brian Poindexter; Heinrich Taegtmeyer; Ann Wamsley; Ranjit Padda; Mark Entman; Søren Nielsen; Keith Youker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-03-27       Impact factor: 4.733

Review 4.  The stanniocalcin family of proteins.

Authors:  Graham F Wagner; Gabriel E Dimattia
Journal:  J Exp Zool A Comp Exp Biol       Date:  2006-09-01

5.  Transcriptional response to hypoxia in human tumors.

Authors:  A Lal; H Peters; B St Croix; Z A Haroon; M W Dewhirst; R L Strausberg; J H Kaanders; A J van der Kogel; G J Riggins
Journal:  J Natl Cancer Inst       Date:  2001-09-05       Impact factor: 13.506

6.  Thyroid hormone inhibits fibronectin synthesis by cultured human skin fibroblasts.

Authors:  Y Murata; P Ceccarelli; S Refetoff; A L Horwitz; N Matsui
Journal:  J Clin Endocrinol Metab       Date:  1987-02       Impact factor: 5.958

7.  Characterization of mammalian stanniocalcin receptors. Mitochondrial targeting of ligand and receptor for regulation of cellular metabolism.

Authors:  Christopher R McCudden; Kathi A James; Craig Hasilo; Graham F Wagner
Journal:  J Biol Chem       Date:  2002-09-09       Impact factor: 5.157

Review 8.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

9.  Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface.

Authors:  Faith B Davis; Shaker A Mousa; Laura O'Connor; Seema Mohamed; Hung-Yun Lin; H James Cao; Paul J Davis
Journal:  Circ Res       Date:  2004-04-29       Impact factor: 17.367

Review 10.  Mammalian stanniocalcins and cancer.

Authors:  A C-M Chang; D A Jellinek; R R Reddel
Journal:  Endocr Relat Cancer       Date:  2003-09       Impact factor: 5.678

View more
  5 in total

1.  Expression of stanniocalcin 1 in thyroid side population cells and thyroid cancer cells.

Authors:  Suguru Hayase; Yoshihito Sasaki; Tsutomu Matsubara; Daekwan Seo; Masaaki Miyakoshi; Tsubasa Murata; Takashi Ozaki; Kennichi Kakudo; Kensuke Kumamoto; Kris Ylaya; Sheue-yann Cheng; Snorri S Thorgeirsson; Stephen M Hewitt; Jerrold M Ward; Shioko Kimura
Journal:  Thyroid       Date:  2015-03-23       Impact factor: 6.568

2.  Transcriptional regulation by nonclassical action of thyroid hormone.

Authors:  Lars C Moeller; Martina Broecker-Preuss
Journal:  Thyroid Res       Date:  2011-08-03

Review 3.  Transport of thyroid hormones via the choroid plexus into the brain: the roles of transthyretin and thyroid hormone transmembrane transporters.

Authors:  Samantha J Richardson; Roshen C Wijayagunaratne; Damian G D'Souza; Veerle M Darras; Stijn L J Van Herck
Journal:  Front Neurosci       Date:  2015-03-03       Impact factor: 4.677

Review 4.  Thyroid hormone-dependent oligodendroglial cell lineage genomic and non-genomic signaling through integrin receptors.

Authors:  Rahimeh Emamnejad; Mary Dass; Michael Mahlis; Salome Bozkurt; Sining Ye; Maurice Pagnin; Paschalis Theotokis; Nikolaos Grigoriadis; Steven Petratos
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

5.  THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.

Authors:  Ikuya Miki; Tsutomu Nakamura; Akiko Kuwahara; Motohiro Yamamori; Kohshi Nishiguchi; Takao Tamura; Tatsuya Okuno; Hideaki Omatsu; Shigeto Mizuno; Midori Hirai; Takeshi Azuma; Toshiyuki Sakaeda
Journal:  Int J Med Sci       Date:  2012-10-23       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.